Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» ESMO
ESMO
ESMO21: Libtayo extends survival in first-line NSCLC, challenging Keytruda
Pharmaforum
Mon, 09/20/21 - 11:07 am
Sanofi
Regeneron
Libtayo
ESMO
non-small cell lung cancer
Merck
Keytruda
ESMO: Mirati pulls away from Amgen in colorectal cancer with rival KRAS drug
Fierce Biotech
Mon, 09/20/21 - 12:00 am
ESMO
Mirati Therapeutics
Amgen
colorectal cancer
Novartis presents new Kisqali data showing longest median overall survival ever reported in HR+/HER2- advanced breast cancer
Drugs.com
Sun, 09/19/21 - 11:58 pm
ESMO
Novartis
clinical trials
Kisqali
breast cancer
AstraZeneca, Daiichi Sankyo's ADC Enhertu blows away Roche's Kadcyla in second-line advanced breast cancer
Endpoints
Sat, 09/18/21 - 08:34 pm
ESMO
AstraZeneca
Daiichi Sankyo
Enhertu
breast cancer
Roche
Merck fleshes out Keytruda win in first-line cervical cancer, adding more firepower to its early cancer push
Endpoints
Sat, 09/18/21 - 08:29 pm
ESMO
Merck
Keytruda
Roche
Avastin
cervical cancer
ESMO: Exelixis lays out promising early Cabometyx combo data in prostate cancer, but key discrepancies persist
Fierce Pharma
Sat, 09/18/21 - 08:27 pm
ESMO
Exelixis
Cabometyx
Roche
Tecentriq
clinical trials
prostate cancer
ESMO: Pfizer, Astellas' latest Xtandi survival data may shore up prostate cancer lead over J&J
Fierce Pharma
Sat, 09/18/21 - 08:26 pm
ESMO
Pfizer
Astellas
Xtandi
prostate cancer
clinical trials
ESMO21: Roche’s giredestrant takes stage in battle of the oral SERDs
Pharmaforum
Fri, 09/17/21 - 11:36 am
Roche
Giredestrant
Serds
breast cancer
ESMO
AstraZeneca
Faslodex
ESMO: Daiichi unveils first early peek at next-gen ADC as analysts see strong data against rivals
Fierce Biotech
Fri, 09/17/21 - 11:06 am
ESMO
Daiichi Sankyo
antibody-drug conjugate
DS-7300
ESMO 2021 – the jury remains out on CDK7 inhibition
EP Vantage
Fri, 09/17/21 - 11:02 am
ESMO
Syros Pharmaceuticals
Carrick Therapeutics
breast cancer
ESMO: Novartis links prostate cancer drug to improved pain, quality of life as regulatory filings near
Fierce Biotech
Thu, 09/16/21 - 11:04 pm
Novartis
ESMO
clinical trials
prostate cancer
ESMO: Facing new Keytruda combos from Merck, BMS touts 5-year kidney cancer data for Opdivo-Yervoy
Fierce Pharma
Thu, 09/16/21 - 10:56 am
Bristol Myers Squibb
Opdivo
Yervoy
kidney cancer
ESMO
Gilead keeps pushing trove of Trodelvy data as it seeks to become new standard of care in TNBC
Endpoints
Thu, 09/16/21 - 10:42 am
ESMO
Gilead Sciences
Trodelvy
triple negative breast cancer
ESMO Preview: Highlights to Watch for This Year
BioSpace
Wed, 09/15/21 - 10:29 pm
ESMO
oncology
cancer
Gilead Sciences
Bristol Myers Squibb
Zymeworks
Amgen
Adaptimmune Therapeutics
TCR2 Therapeutics
Boehringer Ingelheim
ESMO 2021 – Mirati bids to be belle of the ball
EP Vantage
Tue, 09/14/21 - 10:41 am
ESMO
Mirati Therapeutics
Faron Pharmaceuticals
Amgen
Spectrum Pharmaceuticals
Gilead scores US approval for breast cancer drug that wowed ESMO
Pharmaforum
Thu, 04/8/21 - 10:23 am
Gilead Sciences
Trodelvy
FDA
ESMO
triple negative breast cancer
Autolus buckles down, chopping 20% of staff and seeking partner for a lead CAR-T program
Endpoints
Wed, 01/6/21 - 10:58 am
Autolus Therapeutics
ESMO
CAR-T
diffuse large B-cell lymphoma
layoffs
Did Gilead overpay for Immunomedics? Trodelvy answered that $21B-dollar question at ESMO: analyst
Fierce Pharma
Thu, 09/24/20 - 11:26 pm
Gilead Sciences
Immunomedics
M&A
Trodelvy
ESMO
breast cancer
Esmo 2020 – can Alkermes succeed where Nektar failed?
EP Vantage
Wed, 09/23/20 - 10:33 am
Alkermes
ESMO
ALKS 4230
melanoma
AstraZeneca’s Tagrisso Continues to Make Strides in Phase III Lung Cancer Trial
BioSpace
Tue, 09/22/20 - 11:10 am
AstraZeneca
clinical trials
Tagrisso
ESMO
non-small cell lung cancer
Pages
« first
‹ previous
1
2
3
4
5
6
next ›
last »